Travere Therapeutics (TVTX) CEO sells 60K shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.
The sales were split between 34,902 shares at $30.55 and 25,098 shares at $31.46, executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2025. After these transactions, Dube directly holds 432,886 shares of Travere common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 60,000 shares ($1,855,839)
Net Sell
4 txns
Insider
Dube Eric M
Role
CHIEF EXECUTIVE OFFICER
Sold
60,000 shs ($1.86M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee stock option (right to buy) | 60,000 | $0.00 | -- |
| Exercise | Common Stock | 60,000 | $15.46 | $928K |
| Sale | Common Stock | 34,902 | $30.55 | $1.07M |
| Sale | Common Stock | 25,098 | $31.46 | $790K |
Holdings After Transaction:
Employee stock option (right to buy) — 0 shares (Direct);
Common Stock — 492,886 shares (Direct)
Footnotes (1)
- This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable.
Key Figures
Options exercised: 60,000 shares
Exercise price: $15.46/share
Shares sold at $30.55: 34,902 shares
+4 more
7 metrics
Options exercised
60,000 shares
Employee stock option exercise at $15.46 on April 1, 2026
Exercise price
$15.46/share
Exercise or conversion price of employee stock option
Shares sold at $30.55
34,902 shares
Open-market sale at weighted average $30.55 on April 1, 2026
Shares sold at $31.46
25,098 shares
Open-market sale at weighted average $31.46 on April 1, 2026
Total shares sold
60,000 shares
Combined open-market sales on April 1, 2026
Post-transaction holdings
432,886 shares
Common stock directly owned after transactions
Option expiration
January 31, 2030
Expiration date of the exercised employee stock option
Key Terms
Employee stock option, Rule 10b5-1(c), weighted average sale price, open-market sale, +1 more
5 terms
Employee stock option financial
"security_title: "Employee stock option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Rule 10b5-1(c) regulatory
"written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $30.55"
open-market sale financial
"transaction_action: "open-market sale" for Common Stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transactions did Travere Therapeutics (TVTX) CEO Eric Dube report?
Eric Dube reported exercising options for 60,000 Travere shares at $15.46 and selling those 60,000 shares in two open-market transactions at $30.55 and $31.46 per share on April 1, 2026.
What stock option did the Travere Therapeutics (TVTX) CEO exercise in this filing?
The CEO exercised a fully vested employee stock option granted on January 31, 2020 for 60,000 shares of Travere common stock at an exercise price of $15.46 per share. The option was described as fully vested and exercisable in the filing.